TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05903963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
Study: NCT06121596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
Study: NCT05737238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention
Description: The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
Study: NCT04970771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solving Wellness platform
Description: Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
Study: NCT04689750

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing.
Study: NCT05115279

Intervention type: PROCEDURE
Group type: OTHER
Intervention: breast conservative surgery for post chemotherapy tumour size
Description: * Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique
Study: NCT04898374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabin/cisplatin
Description: chemotherapy combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabin/cisplatin
Description: chemotherapy combination
Study: NCT05315401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
Study: NCT05563246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally
Study: NCT06186232

Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided bone regeneration (GBR).
Description: guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
Study: NCT04547556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire
Description: A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)
Study: NCT06411938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-collection of vaginal swabs
Description: Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
Study: NCT06389656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Management
Description: Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Bias Internalization
Description: Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
Study: NCT05689021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate/Niraparib
Description: Given PO
Study: NCT05563246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04922658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Plus Vinorelbine
Description: Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
Study: NCT06432569

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ButirBioma + PeaBioma
Description: randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo( 3+3 cps/die)
Study: NCT05689021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo technetium-99m bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT06152484

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and CASIA2
Description: morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and CASIA2
Description: morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and CASIA2
Description: morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
Study: NCT05923762

Intervention type: BEHAVIORAL
Intervention: OHRQoL
Description: Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)
Study: NCT05608018

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Bluetooth
Description: Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention non-Bluetooth
Description: Participants will not receive a Bluetooth device, and will use the app with all features turned on.
Study: NCT05609448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-guided radioembolization
Description: Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
Study: NCT05415046

Intervention type: PROCEDURE
Intervention: Sacral ESPB
Description: Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
Study: NCT05608018

Intervention type: OTHER
Group type: OTHER
Intervention: Control Bluetooth
Description: Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.

Intervention type: OTHER
Group type: OTHER
Intervention: Control non-Bluetooth
Description: Participants will not receive a Bluetooth device, and will use the app with some features turned off.
Study: NCT06471829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG13909
Description: Solution for injection/infusion
Study: NCT05061953

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT06202599

Intervention type: DRUG
Intervention: Fruquintinib
Description: For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
Study: NCT04912570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Thrombus Aspiration
Description: Manual thrombus aspiration using one of the FDA approved aspirators will be done.
Study: NCT05691660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3731 Dose1
Description: Oral administration,1 day,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3731 Dose2
Description: Oral administration,7 days,QD
Study: NCT06306183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Vitamin C with Naproxen rescue
Description: 900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen and Placebo with Naproxen rescue
Description: Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen.
Study: NCT05691660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3731 Dose3
Description: Oral administration,7 days,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration, 1 day,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration, 7 days,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration, 7 days,BID
Study: NCT04912570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: Standard PCI according to the most recent guidelines
Study: NCT04898738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol based hand sanitizer
Description: Provision of ABHS to randomly selected households
Study: NCT06441812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703 Injection
Description: SHR-1703 Injection
Study: NCT06553989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopatic visceral mobilization
Description: a combination of breathing and visceral mobilizations
Study: NCT06435260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+chemotherapy
Description: Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Hypofractionated radiotherapy: pGTV:40Gy/5F, PTV≥25Gy/5F.
Study: NCT06535958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHI
Description: All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHI
Description: All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
Study: NCT05630404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ESPB
Description: In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US guided ESPB
Description: US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
Study: NCT06131346

Intervention type: OTHER
Intervention: Evaluation of clinical and paraclinical data.
Description: Retrospective data collection from available medical files of patient.
Study: NCT05345834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Cognitive-Behavioral Therapy
Description: Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
Study: NCT04716192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique
Description: Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release technique & Ultrasound
Description: Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique & Ultrasound
Description: Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest.
Study: NCT06535958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OHI+PMPR
Description: Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
Study: NCT05677178

Intervention type: OTHER
Intervention: observational
Description: This study is an observational study without any intervention.

Intervention type: OTHER
Intervention: observational
Description: This study is an observational study without any intervention.
Study: NCT05860140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education video
Description: Six minutes long education video focusing on protein and energy meals